Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 13/20 | 1.00 |
| ▸ | CA1 | P00915 | 13/20 | 1.00 |
| ▸ | CA2 | P00918 | 13/20 | 1.00 |
| ▸ | CA9 | Q16790 | 13/20 | 1.00 |
| ▸ | CA4 | P22748 | 10/20 | 1.00 |
| ▸ | CA6 | P23280 | 10/20 | 1.00 |
| ▸ | CA7 | P43166 | 10/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 10/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 10/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 10/20 | 1.00 |
| ▸ | CA3 | P07451 | 9/20 | 1.00 |
| ▸ | CA5A | P35218 | 8/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31717970 | 1.00 | CA12 (1.00) | CA12CA1CA2CA9CA4 | |
| Hydrochloric Acid SCHEMBL11158505 | 0.98 | CA12 (0.96) | CA12CA1CA2CA9CA4 | |
| SCHEMBL11232241 | 0.87 | CISD1 (0.77) | CA12CA1CA2CA9CA4 | |
| SCHEMBL3040620 | 0.85 | CISD1 (0.74) | CA12CA1CA2CA9CA4 | |
| SCHEMBL22499516 | 0.85 | CA12 (0.74) | CA12CA1CA2CA9CA4 | |
| SCHEMBL11198069 | 0.85 | CISD1 (0.74) | CA12CA1CA2CA9CA4 | |
| SCHEMBL10685397 | 0.85 | CA12 (0.73) | CA12CA1CA2CA9CA4 | |
| SCHEMBL1809228 | 0.85 | CA1 (1.00) | CA12CA1CA2CA9CA4 | |
| SCHEMBL11711824 | 0.84 | CISD1 (0.72) | CA12CA1CA2CA9CA4 | |
| SCHEMBL2876194 | 0.84 | CISD1 (0.72) | CA12CA1CA2CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| EP-3328833-B1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | UNIV VILNIUS (LT) | 2025-08-06 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-116178317-A | Furosemide production process | 台山市新宁制药有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-112142833-B | Furosemide artificial antigen, antibody and application thereof in detection of furosemide | 华南农业大学 | 2021-10-29 | — | — | CN | claimed |
| CN-112142833-A | Furosemide artificial antigen, antibody and application thereof in detection of furosemide | 华南农业大学 | 2020-12-29 | — | — | CN | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| EP-1747229-A1 | STEROID PRODRUGS WITH ANDROGENIC EFFECT | Schering Aktiengesellschaft (DE) | 2007-01-31 | — | — | EP | claimed |
| WO-2005113575-A1 | STEROID PRODRUGS WITH ANDROGENIC EFFECT | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-01 | — | — | WO | claimed |
| EP-0132540-A1 | Antiviral compositions | Mochida Pharmaceutical Co., Ltd. (JP) | 1985-02-13 | — | — | EP | claimed |
| EP-0068408-A1 | Antiviral compositions and a method for treating virus diseases | Mochida Pharmaceutical Co., Ltd. (JP) | 1983-01-05 | — | — | EP | claimed |
| EP-0068407-A1 | Aminosulfonylbenzoic acid derivatives | HODOGAYA CHEMICAL CO., LTD. (JP) | 1983-01-05 | — | — | EP | claimed |
| JP-57212154-A | — | — | None | — | — | JP | disclosed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| JP-S57212154-A | NOVEL AMINOSULFONYLBENZOIC ACID DERIVATIVE | HODOGAYA CHEM CO LTD | 1982-12-27 | — | — | JP | disclosed |
| US-4001284-A | PRIMARY AMINES, 2,4-DIPHENOXY-5-SULFAMOYLBENZOIC ACID | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | CA12 4479/4885CA1 4047/4885CA2 3509/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | CA12 658/4885CA1 1546/4885CA2 672/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | CA12 4479/4885CA1 4047/4885CA2 3509/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | CA12 4479/4885CA1 4047/4885CA2 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.